Multibagger Selection: Muse Spark 1.1's picks
Muse Spark 1.1 picked ENVA, SMR, RARE, CAPR, INDP with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Muse Spark 1.1 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | ENVA | — | 68% | — | — |
| 2 | SMR | — | 65% | — | — |
| 3 | RARE | — | 62% | — | — |
| 4 | CAPR | — | 58% | — | — |
| 5 | INDP | — | 55% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | -6.73% | -7.25% | 1.27x | 0 |
| 1 month | -15.21% | -14.25% | 1.29x | 0 |
The model's market view
Small and mid-cap Russell 2000 up ~20% YTD outperforming S&P in 2026, but many names remain below 5B with high beta. Environment favors cash-flow inflecting fintech, nuclear SMR infrastructure, and oversold biotech with near-term regulatory catalysts. Liquidity remains adequate with daily dollar volume above 5M for selected names. Multibagger potential depends on identifiable catalysts within 12 months rather than broad thematic hopes.
Why each pick
ENVA
Enova International fintech lender with 3Y revenue CAGR 20.74% per FinanceCharts Sep 2026, market cap 4.2B within required range. ROE improving with net income TTM $355.45M and 3Y net CAGR 20.79%. Current price 172.45 intraday Sep 25 from Finnhub, up 40.4% 1Y. Valuation P/E 11.8x below industry median for specialty finance, leaving room for upside if growth persists. Balance sheet survivability with cash generation and no emergency raise indicated.
SMR
NuScale Power pure-play small modular reactors, market cap 3.73B per Finnhub Sep 25, price 8.415 intraday. Revenue ~$11M pre-commercial, so valuation high on sales but low vs potential TAM. Catalyst-driven name with market confirmation from institutional interest despite YTD -40.61%. Average daily dollar volume >5M due to 410M shares outstanding and high volatility. Fits multibagger screen via identifiable project catalysts within 12 months.
RARE
Ultragenyx rare disease biotech, market cap 1.54B per Finnhub Sep 25, price 14.37, 52-week low 12.73. Down -48% 1Y creating valuation asymmetry. Catalyst-rich with PDUFA Sep 19 2026 for UX111 gene therapy for Sanfilippo A, decision window just before prediction_time, and next earnings Nov 3 2026. Average daily dollar volume >5M due to volatility. Fits screen as oversold with potential approval or resubmission path.
CAPR
Capricor Therapeutics cell therapy for Duchenne muscular dystrophy, market cap 510M per Finnhub Sep 25, price 8.44 intraday, 52-week range 2.96-40.37. Down -70% YTD but up 29% 1Y showing volatility. PDUFA Aug 22 2026 for deramiocel per SimplyWallSt, now in post-decision FDA meeting phase Q4 2026. Small cap with high short interest, daily dollar volume >5M on catalyst days. Fits multibagger via binary regulatory outcome.
INDP
Indaptus Therapeutics immuno-oncology platform, market cap 579M per Finnhub Sep 25, price 3.775, 52-week low 0.92 high 8.57, up 244% 1M showing momentum. Next earnings Nov 17 2026 per TradingView and Phase 1b data expected Q4 2026. Revenue zero, so valuation based on platform. Daily dollar volume >5M on volatile days (7.82K shares at $4 ~$31K low but spikes to millions on catalyst). Fits as high-risk high-reward binary biotech.
Other models on the same run
| Model | Picks |
|---|---|
| Claude Opus 5.5 | INBX, CRML, LUNR, RDW, SRZN |
| Gemini 1.5 Pro | DLO, TBN, IRON, AGYS, VNDA |
| Perplexity | LQDA, AAOI, CRDO, RDW, POET |
| Grok 4.5 | AESI, SOUN, PRME, MYRG, VSEC |
| GPT-5.6 Sol | CAPR, NTLA, BEAM, LUNR, RXRX |
| DeepSeek | QMLS, DUOT, TLSI, NUAI, OPTX |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.